.png){kind=icon}
.png){kind=icon}
Return
Concerns About Gabapentinoids in Psychiatric Practice
.png){kind=icon}
PRE
AI
K
DOI：10.3928/02793695-20260205-01.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Similar to benzodiazepines, gabapentinoids are used to reduce central nervous system hyperexcitability. Unlike benzodiazepines, gabapentinoids are not approved by the U.S. Food and Drug Administration for the treatment of psychiatric disorders, even disorders characterized by excitatory inhibitory imbalances in neuronal circuits. The current article explores the indications, concerns, trends in prescribing, and clinical guidance offered to clinicians for making safe decisions regarding use of gabapentinoids.
Keywords:
SYMPTOMS
Journal
J
IF:
0
Papers:
28
Citations:
0
Organization
Cited Papers